The study of the anti-malignant
tumor effect of refined Anbol
Drug Research Center Of Lonjer
Abstract
To observe the effect of refined
Anbol on the growth of rat sarcoma W256 and its life
prolonging effect on E’s ascites cancer in mice. The results showed
that the refined Anbol could significantly inhibit the growth
of rat sarcoma W256 with a inhibit rate of 37.7%, and
it could prolong the life of e’s ascites cancer mice with a prolonging
rate of 35.8%.
Key
words: refined Anbol, Walker carcinosarcoma
256 (W256), E’s ascites cancer (EAC)
The brown powder solid prepared
by our factory with Anbol in Ningxia province as raw material
and through extracting, refining, and purifing was named “refined
Anbol” since its condensation of the essence of Anbol in Ningxia
province. It is rich in many physiological activity components
such as Anbol, amino acid and trace elements etc., and it has
the funciton of immune function enhancing, thymus atrophy improving,
and anti-aging. In this study the implant carcinosarcoma w256
in rats and implant E’s E’s ascites cancer (EAC) in mice were
used as the tumor model, and refined Anbol was used as experimental
material, and experimental research was done to its anti-tumoring
effect.
1 Materials
1.1
Materials The matured
and dried fruits of Anbol in Ningxia province were extracted with
water, precipitated with alcohol, isolated, refined, and the brown
powder solid named refined Anbol obtained, and the rate of extraction
was 3%. It was produced by traditional chinese herbs factory in
Ningxia province, with the batch number as 930507. It was dissolved
to corresponding concentration using distilled water before experiment.
1.2
Experiment animals Wistar
rats, weighing about 70g, male; Kunming mice weighing 18 to 22
g , male; rate W256 ascites tumor and mice E’s ascites cancer
source murine, tumor time 7 to 9 days, provided by oncology department
in chinese drugs institute.
2
Methods and results
2.1
The rats carcinosarcoma W256 inhibition effect of refined Anbol
The experiment had 5 groups,
which were refined Anbol group (0.45g/kg, 0.30 g/ kg and 0.15g/kg),
cyclophosphamide (CTX) group 10g/kg, and saline control group.
50 male Wistar rats were randomly divided into 5 groups with 10
rats in each group; the ascites of W256 ascites cancer source
rats was drew and vaccinated to the subcutaneous tissue at right
fore-limb on armpit of experimental rats according to regular
methods. 24 h after the vaccination, the drug was administrated
respectively for 7 days with one time each. The rats were sacrificed
24 h after the last administration, and the tumor lump was taken
out completely and was weighed. The tumor inhibition rate was
calculated and compared with that in control group, and t-test
was used to do statistical analyse on the mean tumor weight between
groups. The experiment was repeated 3 times, and the results were
as showed by table 1).
The results showed that the
positive control drug CTX could significantly inhibit the growth
of rats carcinosarcoma W256 with a tumor inhibition rate of 95.6%;
compared with saline control, refined Anbol with dose of 0.45g/kg,and
0.30g/kg had very significant tumor inhibiting effect to rats
carcinosarcoma W256 (P<0.01), with the tumor inhibition rate
as 37.7% and 37.2% respectively. It can be observed from the results
showed in the table that the tumor inhibiting effect of refined
Anbol had positive correlation trend with its dose, while the
tumor inhibiting effect of low dose refined Anbol was not significant.
2.2
life prolonging effect of refined Anbol on E’s Ascites Cancer mice.
5 groups were included in this
experiment, which were refined Anbol group (0.6g/kg, 0.3g/kg and
0.15 g /kg) , fluorouracil group(5-Fu) 20mg/kg, and saline contral
group.50 male Kunming rats were divided randomly into 5 groups
with 10 rats each. The ascites of E’s ascites cancer source mice
were drew and diluted with saline to 1:3, and 0.2ml/rat tumor
cell fluid was injected into mice peritoneally on the condition
of sterility, and drugs were administrated 24 h later for 10 days
with on time each day. The living time were observed, and the
investigation was done 3 times, and the life prolonging rate were
calculated. T-test was used to compare the diffenrence of mean
living days number between groups. The results were showed in
table 2.
The experiment results showed
that, positive control group and 5-Fu could significantly prolong
the life of E’s Ascites Cancer mice with a prolonging rate of
52.0%, and had significant difference compared with saline control
group (p<0.01). Different dose of refined Anbol could all prolong
the life of EAC mice with life prolonging rate of 24.6~35.8, which
all had significant difference compared with that of saline control
(P<0.05 and P<0.01.
3.Discussion
The anti-tumor study for refiend
Anbol showed that this drug can significantly inhibit the growth
fo rats W256 tumor, and prolong the life of E’s Ascites Cancer
mice(P<0.01). The study was repeated for three times, which
demonstrated that this drug had certain anti-tumor effects which
provided data and basis for drug using in clinic. Refined Anbol
was health care drugs produced by our factory.
However, further study needed
to find what kind of immune mechanism attaining the anti-tumor
effect and to analyse the anti-tumer active components.
Table 1
The rats carcinosarcoma W256 inhibition effect of refined
Anbol
|
No
of experiment
|
Groups
and doses
|
Number
of animals
|
Weight
of tumor
(g) M±s
|
Inhibition
rate
|
|
Batch
1
|
N.S
control
|
10
|
5.07±1.74
|
|
|
CTX10mg/kg×7
|
10
|
0.18±0.10***
|
96.4
|
|
Refined
Anbol
0.45g/kg×7
|
10
|
3.73±0.91*
|
26.4
|
|
Refined
Anbol
0.30g/kg×7
|
10
|
3.69±0.83*
|
27.2
|
|
Refined
Anbol
0.15g/kg×7
|
10
|
5.11±1.73
|
0
|
|
Batch
2
|
N.S
control
|
10
|
5.65±1.46
|
|
|
CTX10mg/kg×7
|
10
|
0.377±0.12***
|
93.3
|
|
Refined
Anbol
0.45g/kg×7
|
10
|
2.195±0.80***
|
61.2
|
|
Refined
Anbol
0.30g/kg×7
|
10
|
3.495±1.49**
|
38.1
|
|
Refined
Anbol
0.15g/kg×7
|
10
|
3.817±0.80**
|
32.4
|
|
Batch
3
|
N.S
control
|
10
|
4.90±1.80
|
|
|
CTX10mg/kg×7
|
10
|
0.14±0.08***
|
96.9
|
|
Refined
Anbol
0.45g/kg×7
|
10
|
3.81±1.43
|
22.2
|
|
Refined
Anbol
0.30g/kg×7
|
10
|
2.63±1.00**
|
46.3
|
|
Refined
Anbol
0.15g/kg×7
|
10
|
3.95±0.97
|
19.4
|
|
groups
|
doses
|
Injection
methods
|
Number
of rats
|
Weight
of tumor
(g) M±s
|
Inhibition
rate
|
|
Saline
|
0.02ml/kg
|
p.o
|
30
|
5.200±1.65
|
|
|
CTX
|
10mg/kg
|
i.p.
|
30
|
0.230±0.15**
|
95.6
|
|
Refined
Anbol
|
.45g/kg
|
p.o
|
30
|
3.24±1.29**
|
37.7
|
|
Refined
Anbol
|
0.30g/kg
|
p.o
|
30
|
3.270±1.20**
|
37.2
|
|
Refined
Anbol
|
0.15g/kg
|
p.o
|
30
|
4.291±1.33
|
17.5
|
p.o., administrated through
mouth; i.p., intraperitoneal injection; **compared with saline group P<0.01;
***P<0.001.
Table 2 life prolonging
effect of refined Anbol on E’s Ascites Cancer mice.
|
Batch
no.
|
groups
|
doses
|
Injection
methods
|
Number
of rats
|
Mean
days of survived (M±s)
|
Life
prolonging rate (%)
|
|
Batch
1
|
Saline
|
0.02ml/kg
|
p.o
|
10
|
15.0±4.29
|
|
|
5-Fu
|
10mg/kg
|
i.p.
|
10
|
23.4±10.5*
|
56
|
|
Refined
Anbol
|
.45g/kg
|
p.o
|
10
|
19.6±6.3
|
30.7
|
|
Refined
Anbol
|
0.30g/kg
|
p.o
|
10
|
23.3±8.1*
|
55.3
|
|
Refined
Anbol
|
0.15g/kg
|
p.o
|
10
|
20.6±5.1*
|
37.3
|
|
Batch
2
|
Saline
|
0.02ml/kg
|
p.o
|
10
|
14.3±4.27
|
|
|
5-Fu
|
10mg/kg
|
i.p.
|
10
|
22.5±8.04**
|
57.3
|
|
Refined
Anbol
|
.45g/kg
|
p.o
|
10
|
18.5±5.36
|
29.4
|
|
Refined
Anbol
|
0.30g/kg
|
p.o
|
10
|
18.1±1.37*
|
26.6
|
|
Refined
Anbol
|
0.15g/kg
|
p.o
|
10
|
20.2±2.94**
|
41.3
|
|
Batch
3
|
Saline
|
0.02ml/kg
|
p.o
|
10
|
15.3±2.31
|
|
|
5-Fu
|
10mg/kg
|
i.p.
|
10
|
20.7±5.355***
|
35.3
|
|
Refined
Anbol
|
.45g/kg
|
p.o
|
10
|
17.5±1.746*
|
14.4
|
|
Refined
Anbol
|
0.30g/kg
|
p.o
|
10
|
19.2±0.42***
|
25.5
|
|
Refined
Anbol
|
0.15g/kg
|
p.o
|
10
|
18.1±1.45**
|
18.3
|
p.o., administrated through
mouth; i.p., intraperitoneal injection; **compared with saline group P<0.01;
***P<0.001.